Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 11, 2025 • 3:00 AM ET

Date/Time Source News Release
06/05/2025 07:32 AM EDT GlobeNewswire Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment
05/20/2025 09:00 AM EDT GlobeNewswire Clearmind Medicine to Host Live Webinar "Gazing Through the Crystal Ball" Featuring Leading Psychedelic Experts
05/12/2025 07:32 AM EDT GlobeNewswire Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction
04/25/2025 07:55 AM EDT GlobeNewswire Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
04/23/2025 08:25 AM EDT GlobeNewswire Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites
04/21/2025 09:15 AM EDT GlobeNewswire Clearmind Medicine to Host Live Webinar "Gazing Through the Crystal Ball" Featuring Leading Psychedelic Experts
04/17/2025 07:38 AM EDT GlobeNewswire Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior
04/16/2025 08:40 AM EDT GlobeNewswire Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism
04/10/2025 08:25 AM EDT GlobeNewswire Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder
04/08/2025 06:55 AM EDT GlobeNewswire Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
Page

Additional News

As of June 11, 2025 • 3:00 AM ET

Date/Time Source News Release
02/26/2024 10:37 AM EST News Direct Clearmind Medicine receives Patent Approval in China for treatment of binge behaviours
01/17/2024 08:30 AM EST InvestorBrandNetwork InvestorNewsBreaks - Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND) (FSE: CWY0) Selects Aegis Capital Corp. as Sole Bookrunner for $2.4M Private Placement
06/07/2022 08:55 AM EDT Financial News Media Rising Cases Of Mental Health Disorders of Stress, Anxiety & Addiction Fueling Need for Central Nervous System Therapeutics
05/24/2022 08:50 AM EDT Financial News Media Global Psychedelics Market Is Expected To Reach $8 Billion By 2029
03/25/2022 09:00 AM EDT InvestorBrandNetwork Interactive Session on Psychedelics for Alcoholism, Q&A with Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) Management
03/22/2022 09:15 AM EDT InvestorBrandNetwork Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) Announces Next Segment in Far-Reaching 'Psychedelics for Alcoholism' Series
02/01/2022 08:30 AM EST InvestorBrandNetwork InvestorNewsBreaks - Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (OTC: CMNDF) to Host Third Event in Psychedelics for Alcoholism Series
01/31/2022 08:30 AM EST InvestorBrandNetwork InvestorNewsBreaks - Clearmind Medicine Inc. (CSE: CMND) (OTC: CMNDF) (FSE: CWY0) Partners with Renowned Expert to Discuss Alcohol Use Disorder and Trauma at Upcoming Virtual Event
01/27/2022 08:30 AM EST InvestorBrandNetwork InvestorNewsBreaks - Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (OTC: CMNDF) Announces Featured Speaker for Psychedelics for Alcoholism series
10/26/2021 08:30 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) Enters Agreement with Aragen Life Sciences to Produce Innovative Drug Candidate
Page
  • 1
  • 2

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.